{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:58:02Z","timestamp":1767146282548,"version":"build-2238731810"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["YDZJ202201ZYTS551"],"award-info":[{"award-number":["YDZJ202201ZYTS551"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejmech.2024.117181","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T12:38:03Z","timestamp":1734611883000},"page":"117181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis and clinical application of new drugs approved by NMPA in 2023"],"prefix":"10.1016","volume":"283","author":[{"given":"Lijuan","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117181_bib1","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s40265-021-01632-9","article-title":"Mobocertinib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117181_bib2","series-title":"Preparation of Pyrimidine Derivative and Pharmaceutical Salts Thereof for the Treatment of Disorders","author":"Durak","year":"2019"},{"key":"10.1016\/j.ejmech.2024.117181_bib3","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib4","series-title":"Clinical and research information on drug-induced liver injury","year":"2012"},{"key":"10.1016\/j.ejmech.2024.117181_bib5","series-title":"Salt (S) of 7-Cyclopentyl-2-(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7h-Pyrrolo [2, 3-d] Pyrimidine-6-Carboxylic Acid Dimethylamide and Processes of Making Thereof","author":"Calienni","year":"2012"},{"key":"10.1016\/j.ejmech.2024.117181_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101952","article-title":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b\/2 trial","volume":"59","author":"Yu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejmech.2024.117181_bib7","series-title":"Five-membered Heterocyclic Pyridine Compounds and Preparation Method and Use Thereof","author":"Jingkang Shen","year":"2018"},{"key":"10.1016\/j.ejmech.2024.117181_bib8","article-title":"Clinical and research information on drug-induced liver injury","author":"Acalabrutinib","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib9","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib10","series-title":"Preparation of Imidazopyrazinylbenzamide Derivatives and Analogs for Use as Btk Inhibitors","author":"Barf","year":"2013"},{"key":"10.1016\/j.ejmech.2024.117181_bib11","article-title":"Clinical and research information on drug-induced liver injury","author":"Selumetinib","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib12","series-title":"Crystal Forms of a 1H-Benzimidazole-6-Carboxamide Hydrogen Sulfate Salt","author":"Squire","year":"2007"},{"key":"10.1016\/j.ejmech.2024.117181_bib13","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib14","article-title":"Clinical and research information on drug-induced liver injury","author":"Copanlisib","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib15","series-title":"Preparation of Substituted 2,3-Dihydroimidazo[1,2-C]quinazoline Derivatives for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis","author":"Hentemann","year":"2008"},{"key":"10.1016\/j.ejmech.2024.117181_bib16","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s40265-023-01946-w","article-title":"Befotertinib: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117181_bib17","series-title":"Crystal Form of Anilinopyrimidine Compound Containing Trifluoroethyl-Substituted Indole and its Salts","author":"Wang","year":"2018"},{"key":"10.1016\/j.ejmech.2024.117181_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.omto.2022.01.001","article-title":"Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity","volume":"24","author":"Liang","year":"2022","journal-title":"Molecular therapy oncolytics"},{"key":"10.1016\/j.ejmech.2024.117181_bib19","series-title":"Preparation of Indolylidenemethylpyrrolecarboxamides as Inhibitors of VEGFR, PDEGFR, KIT, Flt-1, Flt-3, Flt-4, and RET Kinase with Reduced Inhibition of AMPK","author":"Liang","year":"2008"},{"key":"10.1016\/j.ejmech.2024.117181_bib20","series-title":"Sunvozertinib: First Approval, Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts","first-page":"83","author":"Sohita","year":"2023"},{"key":"10.1016\/j.ejmech.2024.117181_bib21","series-title":"Preparation of Pharmaceutical Salts and Polymorphic Forms of an ERBB and BTK Inhibitor","author":"Zheng","year":"2023"},{"key":"10.1016\/j.ejmech.2024.117181_bib22","article-title":"Clinical and research information on drug-induced liver injury","author":"Mitotane","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib23","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1021\/ja01225a058","article-title":"The chemical composition of technical DDT1","volume":"67","author":"Haller","year":"1945","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.117181_bib24","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib25","article-title":"Clinical and research information on drug-induced liver injury","author":"Bosutinib","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib26","series-title":"1,2,4-Triazolo[4,3-b]pyridazine Derivatives as Highly Selective C-Met Kinase Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Cancer","author":"Zhong","year":"2014"},{"key":"10.1016\/j.ejmech.2024.117181_bib27","article-title":"Clinical and research information on drug-induced liver injury","author":"Tepotinib","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1535-7163.MCT-22-0537","article-title":"The preclinical pharmacology of tepotinib-A highly selective MET inhibitor with activity in tumors harboring MET alterations","volume":"22","author":"Albers","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.117181_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40265-020-01317-9","article-title":"Tepotinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117181_bib30","series-title":"Pyrimidinyl Pyridazinone Derivatives, Merck Patent G.m.B.H","author":"Oliver","year":"2015"},{"key":"10.1016\/j.ejmech.2024.117181_bib31","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1021\/op9802071","article-title":"Reduction of an enaminone: synthesis of the diamino alcohol core of ritonavir","volume":"3","author":"Haight","year":"1999","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2024.117181_bib33","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib34","article-title":"Clinical and research information on drug-induced liver injury","author":"Eravacycline","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1021\/jm201465w","article-title":"Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent","volume":"55","author":"Xiao","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117181_bib36","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib37","series-title":"Preparation of Pyridine-Based Compounds as Metalloenzyme Inhibitor Compounds for Treating Diseases in Animals and Plants","author":"Hoekstra","year":"2011"},{"key":"10.1016\/j.ejmech.2024.117181_bib38","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib39","article-title":"Clinical and research information on drug-induced liver injury","author":"Cabotegravir","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib40","first-page":"564","volume":"17","author":"Wang","year":"2015","journal-title":"An efficient and highly diastereoselective synthesis of GSK1265744, a potent HIV integrase inhibitor"},{"key":"10.1016\/j.ejmech.2024.117181_bib41","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib42","article-title":"Clinical and research information on drug-induced liver injury","author":"Lefamulin","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib43","series-title":"Pleuromutilin Glycoside Derivatives","author":"Nagarajan","year":"1978"},{"key":"10.1016\/j.ejmech.2024.117181_bib44","article-title":"Clinical and research information on drug-induced liver injury","author":"Maribavir","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib45","year":"2022"},{"key":"10.1016\/j.ejmech.2024.117181_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02405-21","article-title":"New perspectives on antimicrobial agents: maribavir","volume":"66","author":"Halpern-Cohen","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2024.117181_bib47","series-title":"Preparation of Benzimidazole-Containing Nucleoside Analogs as Virucides","author":"Chamberlain","year":"1996"},{"key":"10.1016\/j.ejmech.2024.117181_bib48","series-title":"Crystal Form of Cyano-Substituted Polypeptide Compound and Preparation Method Therefor","author":"Yang","year":"2024"},{"key":"10.1016\/j.ejmech.2024.117181_bib49","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib50","series-title":"Method for Preparation of AMG 416","author":"Bezemer","year":"2015"},{"key":"10.1016\/j.ejmech.2024.117181_bib51","series-title":"Canadian Agency for Drugs and Technologies in Health Copyright \u00a9 CADTH 2017","year":"2017"},{"key":"10.1016\/j.ejmech.2024.117181_bib52","series-title":"Preparation of Glycerol Phenyl Butyrate Esters as Antitumor Agents","author":"Truog","year":"2013"},{"key":"10.1016\/j.ejmech.2024.117181_bib53","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/14728214.2016.1257608","article-title":"An update on DPP-4 inhibitors in the management of type 2 diabetes","volume":"21","author":"Cahn","year":"2016","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejmech.2024.117181_bib54","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1021\/jm00052a017","article-title":"Synthesis and anticonvulsant activities of alpha-acetamido-N-benzylacetamide derivatives containing an electron-deficient alpha-heteroaromatic substituent","volume":"37","author":"Bardel","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117181_bib55","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib56","article-title":"Clinical and research information on drug-induced liver injury","author":"Ozanimod","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib57","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/d41573-024-00034-2","article-title":"Approvals by the China NMPA in 2023","volume":"23","author":"Zhi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117181_bib58","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2147\/DDDT.S240861","article-title":"An overview of the efficacy and safety of ozanimod for the treatment of relapsing multiple sclerosis","volume":"15","author":"Fronza","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2024.117181_bib59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40267-020-00809-8","article-title":"Ozanimod in relapsing forms of multiple sclerosis: a profile of its use","volume":"37","author":"Shirley","year":"2021","journal-title":"Drugs Ther. Perspect."},{"key":"10.1016\/j.ejmech.2024.117181_bib60","series-title":"Selective Sphingosine 1 Phosphate Receptor Modulators and Methods of Chiral Synthesis of Aryl(indanyl)oxadiazoles and Their Use in the Treatment of S1P1-Associated Diseases","author":"Martinborough","year":"2011"},{"key":"10.1016\/j.ejmech.2024.117181_bib61","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib62","article-title":"Clinical and research information on drug-induced liver injury","author":"Esketamine","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib63","series-title":"Lahr, Jean-Marie Grunenwald, Kertzfeld-Benfeld, Racemic Separation of Ketamine","author":"Klaus Steiner","year":"2000"},{"key":"10.1016\/j.ejmech.2024.117181_bib64","series-title":"CADTH Reimbursement Reviews and Recommendations, Pitolisant Hydrochloride (Wakix): CADTH Reimbursement Review: Therapeutic Area: Narcolepsy, Canadian Agency for Drugs and Technologies in Health","year":"2023"},{"key":"10.1016\/j.ejmech.2024.117181_bib65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0928-0987(01)00106-3","article-title":"Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists","volume":"13","author":"Meier","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2024.117181_bib66","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40265-024-02020-9","article-title":"Dimdazenil: first approval","volume":"84","author":"Syed","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117181_bib67","article-title":"Dimdazenil for the treatment of insomnia: a systematic review and narrative synthesis","author":"Ran","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejmech.2024.117181_bib68","doi-asserted-by":"crossref","first-page":"zsad272","DOI":"10.1093\/sleep\/zsad272","article-title":"Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials","volume":"47","author":"Huang","year":"2024","journal-title":"Sleep"},{"key":"10.1016\/j.ejmech.2024.117181_bib69","series-title":"Preparation of Benzodiazepine Heterocyclic Compounds","author":"Guo","year":"2020"},{"key":"10.1016\/j.ejmech.2024.117181_bib70","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib71","article-title":"Clinical and research information on drug-induced liver injury","author":"Nitisinone","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib72","series-title":"Converting the Enol Ester Precursor of a 2-Benzoyl-1,3-Cycloalkane Dione to the Latter Using Trialkylsilyl Cyanohydrins","author":"Bay","year":"1988"},{"key":"10.1016\/j.ejmech.2024.117181_bib73","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib74","series-title":"Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity and Intermediate Thereof","author":"Takayama","year":"2009"},{"key":"10.1016\/j.ejmech.2024.117181_bib75","series-title":"Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"10.1016\/j.ejmech.2024.117181_bib76","first-page":"3560","article-title":"Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo","volume":"5","author":"Chen","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117181_bib77","first-page":"601","volume":"vol. 12","author":"Gonko","year":"1978"},{"key":"10.1016\/j.ejmech.2024.117181_bib78","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib79","article-title":"Clinical and research information on drug-induced liver injury","author":"Maralixibat","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib80","series-title":"Preparation of Enantiomerically-Enriched Tetrahydrobenzothiepine Oxides by Cyclization of Arylpropanalsulfoxides","author":"Li","year":"1999"},{"key":"10.1016\/j.ejmech.2024.117181_bib81","article-title":"Clinical and research information on drug-induced liver injury","author":"Anastrozole","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib82","series-title":"Preparation of Pyridine Derivatives Useful for Preventing And\/or Treating Peptic Ulcer, Ulcerative Hemorrhage, and Gastric Acid-Related Diseases","author":"Huang","year":"2011"},{"key":"10.1016\/j.ejmech.2024.117181_bib83","volume":"28","author":"Sorbera","year":"2003","journal-title":"Drugs Future"},{"key":"10.1016\/j.ejmech.2024.117181_bib84","series-title":"Preparation of Morphinan Derivatives as Analgesics and Diuretics","author":"Nagase","year":"1993"},{"key":"10.1016\/j.ejmech.2024.117181_bib85","series-title":"Deucravacitinib, StatPearls, StatPearls Publishing Copyright \u00a9 2024","author":"Kalola","year":"2024"},{"key":"10.1016\/j.ejmech.2024.117181_bib86","article-title":"Mother To Baby Fact Sheets, Organization of Teratology Information Specialists (OTIS) Copyright de OTIS, mayo 2023","year":"1994","journal-title":"Brentwood (TN)"},{"key":"10.1016\/j.ejmech.2024.117181_bib87","article-title":"Clinical and research information on drug-induced liver injury","author":"Deucravacitinib","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib88","series-title":"Pyridazinecarboxamide Derivatives Useful as Modulators of IL-12, IL-23 And\/or IFNalpha Responses and Their Preparation and Use in the Treatment of Inflammatory and Autoimmune Diseases","author":"Moslin","year":"2014"},{"key":"10.1016\/j.ejmech.2024.117181_bib89","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2165\/11209310-000000000-00000","article-title":"Bilastine","volume":"72","author":"Carter","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117181_bib90","series-title":"Benzimidazole Derivatives with Antihistaminic Activity","author":"Orjales","year":"1998"},{"key":"10.1016\/j.ejmech.2024.117181_bib91","article-title":"Clinical and research information on drug-induced liver injury","author":"Belumosudil","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib92","series-title":"Preparation of 4-[(1h-Indazol-5-Yl)amino]quinazolines as ROCK1 And\/or ROCK2 Kinase Inhibitors with Improved Pharmacokinetic Properties","author":"Campbell","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib93","article-title":"Clinical and research information on drug-induced liver injury","author":"Ritlecitinib","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.ejmech.2024.117181_bib94","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117181_bib95","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J. Med. Chem."}],"updated-by":[{"DOI":"10.1016\/j.ejmech.2025.117853","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000}}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:06:22Z","timestamp":1762265182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424010638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":95,"alternative-id":["S0223523424010638"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117181","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and clinical application of new drugs approved by NMPA in 2023","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117181"}}